Elevated Intra-Ocular pressure is closely correlated with Glaucoma, a devastating eye disease that is the leading cause of blindness in the elderly population. Glaucoma affects more than 3.5% of the adult population worldwide and represents a >$3B market.
Carefully controlling IOP using eye drops is the treatment of choice, but recent clinical evidence shows that eye pressure is highly variable, and proper treatment can only be achieved by measuring IOP up to several times each day.
The gold standard for measuring IOP is the Goldman Tonometer, but this must be performed by a professional, and requires anesthesia and contact with eye. It is therefore unsuitable for frequent, low cost at home measurements.
There is there for an unmet need for a low cost, safe (non-contact), fast and accurate device for measuring IOP by the patient at the patients’ home.

 

Ophthalmic Sciences develops a first-in-market AI technology to help millions of patients from going blind in a $1.7B/yr serviceable available market by a team with over a century of combined experience backed by the world’s top glaucoma surgeons.
The IOPerfect™, a VR headset-like device based on cutting edge algorithms designed for self-administration at home, bridges the competition’s unmet need for continuous user-friendly, accurate and affordable eye pressure tracking, a key biomarker for glaucoma management.
Through its business model, the product will create or far exceed existing revenue streams for clinicians while offering a high level user experience, promoting a steeper uptake slope while improving patient outcomes.
Combining eyecare and telemedicine that are a focus space of industry attention, the company presents an attractive market value proposition while improving people’s lives.
 
Contact us to learn of current strategic partnering and financing opportunities.